Roche announced the launch of the CE-marked VENTANA MMR IHC Panel, which provides clinicians with a comprehensive group of immunohistochemistry (IHC) tests for patients diagnosed with colorectal cancer. The tests detect certain proteins associated with a DNA repair mechanism called mismatch repair (MMR), and aid in differentiating between sporadic colorectal cancer and probable Lynch syndrome, a hereditary form of colorectal cancer. About 3% of colorectal cancers are associated with Lynch syndrome. Lynch syndrome results in a 50 to 80% lifetime risk of developing colorectal cancer, making it important to identify the syndrome in colorectal cancer patients and at-risk family members. Identification of the syndrome may result in early detection and possible cancer prevention among those with the inherited mutation. The global burden of colorectal cancer is expected to increase by 60% to more than 2.2 million new cases and 1.1 million deaths by 2030. Increasingly, guidelines, including those from the National Institute for Health and Care Excellence (NICE), are recommending universal screening of all newly diagnosed colorectal cancers for Lynch syndrome. The VENTANA MMR IHC Panel includes four assays that target MMR proteins MLH1, PMS2, MSH2 and MSH6, as well as the VENTANA BRAF V600E (VE1) assay. It is available for use on the BenchMark GX, XT and ULTRA instruments.